Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
AbbVie Inc.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Signals scattered
2 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Strong fundamentals
Profitability
3/4
Debt & liquidity
3/3
Efficiency
2/2
Profitability metrics stand well above the sector median, yet the balance sheet and valuation tell a different story. ROE reaches 15,367.3%, and ROIC sits +49% above the median at 17.3%, while FCF growth runs +256% ahead despite a negative year-over-year figure. The F-Score of 8/9 reflects solid operational discipline—no new debt issuance and falling long-term obligations. However, the P/E of 124.5× trades +351% richer than the sector median, and the current ratio at 0.67 falls -52% short of the median 1.40, signaling tighter near-term liquidity. The most recent quarter saw EPS miss consensus slightly. Consensus models align with the realized three-year growth trajectory, and the forward PEG sits in reasonable territory, yet the weak beat rate over eight quarters and the structural liquidity squeeze create tension between the strong cash-generation profile and the premium price tag.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 8/9 | 15 367% | +9% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is strengthening; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
ABBV's FCF growth of 256% above the sector median signals strong cash generation, but monitor whether this momentum sustains through the July 31 report. Pay attention to operating cash flow and capital expenditure trends—any slowdown would narrow the gap versus peers.
The current ratio of 1.40 sits 52% below the sector median, a potential constraint on near-term flexibility. Review the debt schedule and covenant disclosures in the annual report on SEC EDGAR to assess whether this reflects strategic positioning or emerging pressure.
Select two or three companies from the sector table and line up their ROE and P/E multiples against ABBV's 26.6% ROE and 27.6× P/E. This will show whether the high valuation reflects the profitability edge or if the market is pricing in expectations beyond current returns.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: +10%-9%-19%-0%
Over 4 years: 3.344.396.754.07
Over 4 years: +3%-6%+4%+9%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 6 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health | 7/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.